FOR IMMEDIATE RELEASE
DATE: April 22, 2024
Contact: Lisa Owens, 210-601-6647
(SAN ANTONIO, TX and RALEIGH, NC) April 22, 2024 ––NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, and OncoBay Clinical, a leading oncology-focused full-service CRO, are collaborating on six Phase 1 Clinical trials in 10 study site locations globally to advance OncoBay’s innovative drug platforms targeting solid tumors.
These phase 1 studies will measure both dosing and safety for OncoBay’s drug platform designed to reduce or stabilize tumors that have not responded to currently approved treatments. The trial locations include San Antonio, Austin and Dallas, Texas and Fairfax, Virginia.
“OncoBay’s mission is to support oncology clinical trials by accelerating development timelines to impact the lives of people with cancer positively,” said Pam Sneed, VP of Clinical Operations at OncoBay Clinical, “Having NEXT Oncology as part of our OncoNet IO network enhances this mission by bringing valuable scientific expertise with greater access to early-stage oncology patients, enabling potential treatments for cancer patients.”
“When traditional therapies don’t provide results, we are the NEXT Option in care to provide potential solutions to patients in need,” Dr. Anthony Tolcher, NEXT Oncology’s CEO and Founder, stated. “Working with the team at OncoBay Clinical to advance promising new approaches for cancer is the exemplification of our shared mission to solve cancer.”
About OncoBay (now Kapadi)
OncoBay Clinical is a global boutique contract research organization (CRO) specializing in immuno-oncology/cell therapy and other complex oncology programs. OncoBay offers strategic and full-service custom-curated solutions for global pharmaceutical and biotech companies looking to advance their products or devices. Originating from Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence, and integration of technology, including AI analytics, to drive quality and data integrity. Built on years of oncology expertise, an advanced technology framework, a highly aligned site network, and a skilled team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit OncoBay.com and follow us on Facebook, Twitter and LinkedIn.
OncoBay is now becoming Kapadi. The world’s leading oncology and cell therapy CRO is aligning itself with parent company Humaneva. The partnership with Pratia, Hyggio, and Kapadi will allow our companies to fully service patients through the clinical trial process from a full-service perspective. Reach out to us at www.kapadi.com for more information on how we can help commercialize your therapy more quickly.
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.